Cutler Group’s Myriad Genetics MYGN Stock Holding History

Cutler Group’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-21,800	Closed	-$20K	–	4630
2018 Q1	$20K	Buy	21,800 +9,600	+79%	+$325K	﹤0.01%	2299
2017 Q4	$53K	Buy	12,200 +11,300	+1,256%	+$381K	﹤0.01%	1815
2017 Q3	$3K	Sell	900 -21,300	-96%	-$608K	﹤0.01%	4826
2017 Q2	$68K	Buy	+22,200	New	+$471K	﹤0.01%	2184
2016 Q2	–	Sell	-500	Closed	-$1K	–	7051
2016 Q1	$1K	Sell	500 -5,500	-92%	-$207K	﹤0.01%	6055
2015 Q4	$23K	Buy	+6,000	New	+$253K	﹤0.01%	3275

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cutler Group's MYGN Position: Q2 2019 in Review

Cutler Group sold out of Myriad Genetics (MYGN) in Q2 2019, closing a stake of 1,100 shares — an estimated $36K sold.

Cutler Group first reported a position in MYGN in Q4 2015 and held it in 7 quarters. The position peaked at $294K in Q2 2017. 235 funds tracked by Wall St. Rank hold MYGN as of Q2 2019.

Cutler Group reported no remaining Myriad Genetics position as of Q2 2019 after selling out during the quarter.
Cutler Group sold 1,100 Myriad Genetics shares in Q2 2019, an estimated $36K.
Cutler Group first reported a position in Myriad Genetics in Q4 2015 and held it in 7 quarters.
Cutler Group's Myriad Genetics position peaked at $294K in Q2 2017.
235 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2019.

Based on Cutler Group's 13F filing for Q2 2019, filed 9 Aug 2019.